Effects of DSIP in Man

Schneider-Helmert, D; Schoenenberger, G. A.

doi:10.1159/000117964

Cited by 35 publications

(7 citation statements)

References 19 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the present study indicated that 3 doses of DSIP showed at best some weak effects. Schneider-Helmert and Schoenenberger [9] reported to adminis ter DSIP in the morning, whereas in our study it was given at the end of the afternoon. It seems however unlikely that the different time of the administration could explain the Note: The subjective sleep quality scale ranges from 0 (low sleep quality) to 14 (high sleep quality).…”

Section: Discussionmentioning

confidence: 54%

“…Important improvements in the amount and stability of sleep in insomniac patients have been reported after the administration of 3 doses of DSIP [9], This, in addi tion to practical limitations prompted us to adopt a design with the administration of no more than 3 doses of DSIP. The results of the present study indicated that 3 doses of DSIP showed at best some weak effects.…”

Section: Discussionmentioning

confidence: 99%

“…In the afternoon on T1, T2 and T3, between 5 and 7 p.m.. I patient from every matched pair received under dou ble-blind conditions 25 nmol DSIP/kg body weight, in 5 ml of 5% glucose solution, by slow intravenous injection [9]. The matching partner received a glucose solution under identical conditions as pla cebo treatment.…”

Section: Methodsmentioning

confidence: 99%

“…8], with a greater activity of the peptide in more extreme disturbances. In healthy subjects DSIP showed small effects [9]. No sedative or other side effects were reported [9.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients

Bes

Hofman²,

Schuur³

et al. 1992

Neuropsychobiology

View full text Add to dashboard Cite

The influence of delta sleep-inducing peptide (DSIP) on sleep was studied in 16 chronic insomniac patients according to a double-blind matched-pairs parallel-groups design. Subjects slept for 5 consecutive nights in the laboratory. Night 1 was used for adaptation, night 2 for baseline measurements. In the afternoon before the 3rd, 4th and 5th night, half of the patients received intravenously 25 nmol/kg body weight DSIP, and half of the patients a glucose solution (placebo). Measures for sleep structure, objective (polysomnography) and subjective sleep quality and for subjective tiredness were assessed. The results for objective sleep quality indicated higher sleep efficiency and shorter sleep latency with DSIP as compared to placebo. One measure of subjectively estimated tiredness decreased within the DSIP group. Data analysis suggested, however, that the statistically significant effects were weak and in part could be due to an incidental change in the placebo group. As none of the other measures, including subjective sleep quality, showed any change, it was concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…8], with a greater activity of the peptide in more extreme disturbances. In healthy subjects DSIP showed small effects [9]. No sedative or other side effects were reported [9.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients

Bes

Hofman²,

Schuur³

et al. 1992

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…Some patients reported that their sleep stayed improved for individually varying, prolonged periods following DS1P adminis tration [12]. Since impaired daytime func tions are clinically among the most impor tant symptoms of insomnia, it is noteworthy that daytime alertness, performance and even memory functions were found to be higher at daytime following DSIP adminis tration in the morning, suggesting that DSIP might act directly on the regulation of awake behaviour in addition to sleep [10,13,14]. The present study aimed at further elaborat ing these findings within a 24-hour psychophysiological investigation of sleep and day time functions in severe chronic insom niacs.…”

mentioning

confidence: 99%

Effects of Delta-Sleep-Inducing Peptide on 24-Hour Sleep-Wake Behaviour in Severe Chronic Insomnia

Schneider-Helmert¹

1987

Eur Neurol

Self Cite

View full text Add to dashboard Cite

Impaired daytime functions are a significant part of chronic insomnia besides sleep disturbance. Therefore, the effects of intermediate-term delta-sleep-inducing peptide (DSIP) administration on sleep and daytime performance were investigated in 14 middle-aged chronic insomniacs. DSIP was administered under placebo-controlled, double-blind conditions for 7 successive nights. Polysomnograms were obtained for placebo baseline, beginning and end of DSIP treatment, and one placebo posttreatment night; daytime psychological state and mental performance were extensively tested before and after 6 DSIP injections. The treatment substantially improved night sleep with the first and additionally with repeated doses. These effects were maintained for the first posttreatment (placebo) night. Efficiency of night sleep and daytime rest reached the levels of normal controls. Alertness and performance at daytime increased significantly. The study demonstrates the efficacy of DSIP for the treatment of impaired sleep and daytime functions as well.

show abstract

Modulation of immunoactive levels of DSIP and blood‐brain barrier permeability by lighting and diurnal rhythm

Banks

Kastin

Selznick

1985

J of Neuroscience Research

View full text Add to dashboard Cite

The brain and plasma levels of immunoactive delta sleep-inducing peptide (DSIP) as well as the permeability of the blood-brain barrier (BBB) to radioiodinated N-Tyr-DSIP (125I-DSIP) were measured at 0400, 0800, 1200, 1600, 2000, and 2400 hr in rats in a normal 12-hr-light/12-hr-dark cycle and at 0800 in rats in constant light or constant dark. Both brain and blood levels of immunoactivity showed statistically significant diurnal changes, whereas the measurement of BBB permeability varied in a regular fashion over time without the changes reaching statistical significance. Immunoactive levels of DSIP in both the plasma and the brain were higher and permeability of the BBB to 125I-DSIP increased in both the constant light and especially the constant dark groups in comparison with the cycled 0800 group. Diurnal variations continued to occur in the blood levels of immunoactive DSIP in the constant dark animals. Studies with radioiodinated serum albumin (RISA) showed that these findings did not result from a change in brain hemodynamics. Immunoactive levels of DSIP in the plasma correlated with brain immunoactive levels and with BBB permeability to 125I-DSIP. The increase in penetration of 125I-DSIP into the brain that occurred with changes in the lighting cycle appeared to be magnified by pre-treatment with aluminum. The results show interrelationships among various aspects of the neuroendocrine axis for DSIP and their modulation by physiological factors.

show abstract

Effects of DSIP in Man

Cited by 35 publications

References 19 publications

Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients

Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients

Effects of Delta-Sleep-Inducing Peptide on 24-Hour Sleep-Wake Behaviour in Severe Chronic Insomnia

Modulation of immunoactive levels of DSIP and blood‐brain barrier permeability by lighting and diurnal rhythm

Contact Info

Product

Resources

About